Emerging Opportunities for Serotypes of Botulinum Neurotoxins

Background: Two decades ago, botulinum neurotoxin (BoNT) type A was introduced to the commercial market. Subsequently, the toxin was approved by the FDA to address several neurological syndromes, involving muscle, nerve, and gland hyperactivity. These syndromes have typically been associated with ab...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:Toxins
المؤلفون الرئيسيون: John Tapia-Núñez, Michael S. Okun, Aparna Wagle Shukla, Ramon L. Rodriguez, J. Glenn Morris, Zhongxing Peng Chen
التنسيق: مقال
اللغة:الإنجليزية
منشور في: MDPI AG 2012-11-01
الموضوعات:
Botulinum toxin serotypes
neurotoxins subtypes
neuro-pharmacology toxins
الوصول للمادة أونلاين:http://www.mdpi.com/2072-6651/4/11/1196

الانترنت

http://www.mdpi.com/2072-6651/4/11/1196

مواد مشابهة